|
시장보고서
상품코드
1991393
항암제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Oncology Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
항암제 시장 규모는 2025년 2,605억 4,000만 달러에서 2026년부터 2034년까지 CAGR 11.72%로 확대되어 2034년에는 7,064억 1,000만 달러에 달할 것으로 예측됩니다.
세계 암 치료제 시장은 암 발병률의 증가와 의학 연구의 발전으로 인해 괄목할 만한 성장을 거듭하고 있습니다. 암 치료제는 암세포를 표적으로 삼거나 암세포의 증식을 억제하여 다양한 종류의 암을 치료하는 데 사용됩니다. 제약회사와 연구기관들은 환자의 생존율과 치료 결과를 개선하기 위해 혁신적인 치료법을 지속적으로 개발하고 있습니다.
항암제 시장의 성장을 이끄는 몇 가지 요인이 있습니다. 전 세계적으로 암 환자 수가 증가하고 조기 진단에 대한 인식이 높아지면서 효과적인 치료법에 대한 수요가 증가하고 있습니다. 생명공학, 면역치료, 표적치료의 발전으로 치료 옵션이 확대되고, 의료진은 암 치료를 개별화할 수 있게 되었습니다.
연구를 통해 새로운 치료법이 속속 등장하고 있어 항암제 시장의 향후 전망은 여전히 밝습니다. 현재 진행 중인 임상시험과 정밀의료(Precision Medicine)의 발전으로 치료 효과는 더욱 향상될 수 있습니다. 헬스케어 시스템이 첨단 암 치료에 대한 접근성을 확대함에 따라 항암제 시장은 꾸준히 성장할 것으로 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 항암제 시장 : 약물 종류별
제5장 세계의 항암제 시장 : 치료법별
제6장 세계의 항암제 시장 : 적응증별
제7장 세계의 항암제 시장 : 제형별
제8장 세계의 항암제 시장 : 유통 채널별
제9장 세계의 항암제 시장 : 지역별
제10장 경쟁 구도
제11장 기업 개요
KSM 26.04.14The Oncology Drugs Market size is expected to reach USD 706.41 Billion in 2034 from USD 260.54 Billion (2025) growing at a CAGR of 11.72% during 2026-2034.
The global oncology drugs market has experienced significant growth due to the increasing prevalence of cancer and advancements in medical research. Oncology drugs are used to treat various types of cancer by targeting cancer cells or slowing their growth. Pharmaceutical companies and research institutions continue to develop innovative therapies to improve survival rates and treatment outcomes for patients.
Several factors are driving the growth of the oncology drugs market. Rising global cancer cases and growing awareness about early diagnosis have increased demand for effective treatments. Advances in biotechnology, immunotherapy, and targeted therapies have expanded treatment options, allowing healthcare providers to personalize cancer care.
The future outlook for the oncology drugs market remains promising as research continues to produce new treatment approaches. Ongoing clinical trials and advances in precision medicine may further improve treatment effectiveness. As healthcare systems expand access to advanced cancer therapies, the oncology drugs market is expected to grow steadily.
MARKET SEGMENTATION
By Drug Class
- Cytotoxic Drugs
- Targeted Drugs
- Hormonal Drugs
- Others
By Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
By Indication
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Others
By Dosage Form
- Solid
- Liquid
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
COMPANIES PROFILED
- F HoffmannLa Roche Ltd, AbbVie Inc, Novartis AG, Pfizer Inc, Bristol Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, Bayer AG, Merck Co Inc
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL ONCOLOGY DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Drug Class
- 4.2. Cytotoxic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Targeted Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Hormonal Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL ONCOLOGY DRUGS MARKET: BY THERAPY 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Therapy
- 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL ONCOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Indication
- 6.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL ONCOLOGY DRUGS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast Dosage Form
- 7.2. Solid Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
- 8.1. Market Analysis, Insights and Forecast Distribution Channel
- 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 9. GLOBAL ONCOLOGY DRUGS MARKET: BY REGION 2022-2034 (USD MN)
- 9.1. Regional Outlook
- 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.2.1 By Drug Class
- 9.2.2 By Therapy
- 9.2.3 By Indication
- 9.2.4 By Dosage Form
- 9.2.5 By Distribution Channel
- 9.2.6 United States
- 9.2.7 Canada
- 9.2.8 Mexico
- 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.3.1 By Drug Class
- 9.3.2 By Therapy
- 9.3.3 By Indication
- 9.3.4 By Dosage Form
- 9.3.5 By Distribution Channel
- 9.3.6 United Kingdom
- 9.3.7 France
- 9.3.8 Germany
- 9.3.9 Italy
- 9.3.10 Russia
- 9.3.11 Rest Of Europe
- 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.4.1 By Drug Class
- 9.4.2 By Therapy
- 9.4.3 By Indication
- 9.4.4 By Dosage Form
- 9.4.5 By Distribution Channel
- 9.4.6 India
- 9.4.7 Japan
- 9.4.8 South Korea
- 9.4.9 Australia
- 9.4.10 South East Asia
- 9.4.11 Rest Of Asia Pacific
- 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.5.1 By Drug Class
- 9.5.2 By Therapy
- 9.5.3 By Indication
- 9.5.4 By Dosage Form
- 9.5.5 By Distribution Channel
- 9.5.6 Brazil
- 9.5.7 Argentina
- 9.5.8 Peru
- 9.5.9 Chile
- 9.5.10 Rest of Latin America
- 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.6.1 By Drug Class
- 9.6.2 By Therapy
- 9.6.3 By Indication
- 9.6.4 By Dosage Form
- 9.6.5 By Distribution Channel
- 9.6.6 Saudi Arabia
- 9.6.7 UAE
- 9.6.8 Israel
- 9.6.9 South Africa
- 9.6.10 Rest of the Middle East And Africa
Chapter 10. COMPETITIVE LANDSCAPE
- 10.1. Recent Developments
- 10.2. Company Categorization
- 10.3. Supply Chain & Channel Partners (based on availability)
- 10.4. Market Share & Positioning Analysis (based on availability)
- 10.5. Vendor Landscape (based on availability)
- 10.6. Strategy Mapping
Chapter 11. COMPANY PROFILES OF GLOBAL ONCOLOGY DRUGS INDUSTRY
- 11.1. Top Companies Market Share Analysis
- 11.2. Company Profiles
- 11.2.1 F. Hoffmann-La Roche Ltd
- 11.2.2 AbbVie Inc
- 11.2.3 Novartis AG
- 11.2.4 Pfizer Inc
- 11.2.5 Bristol Myers Squibb Company
- 11.2.6 GlaxoSmithKline Plc
- 11.2.7 Eli Lilly And Company
- 11.2.8 AstraZeneca
- 11.2.9 Sanofi
- 11.2.10 Bayer AG
- 11.2.11 Merck & Co. Inc
